During the last session, Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s traded shares were 1.98 million, with the beta value of the company hitting 1.14. At the end of the trading day, the stock’s price was $12.90, reflecting an intraday gain of 11.40% or $1.32. The 52-week high for the DNA share is $64.40, that puts it down -399.22 from that peak though still a striking 59.22% gain since the share price plummeted to a 52-week low of $5.26. The company’s market capitalization is $741.48M, and the average intraday trading volume over the past 10 days was 1.29 million shares, and the average trade volume was 1.31 million shares over the past three months.
Ginkgo Bioworks Holdings Inc (DNA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.83. DNA has a Sell rating from 2 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
Ginkgo Bioworks Holdings Inc (DNA) registered a 11.40% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 11.40% in intraday trading to $12.90, hitting a weekly high. The stock’s 5-day price performance is 50.70%, and it has moved by 46.76% in 30 days. Based on these gigs, the overall price performance for the year is -73.35%. The short interest in Ginkgo Bioworks Holdings Inc (NYSE:DNA) is 7.37 million shares and it means that shorts have 4.88 day(s) to cover.
The consensus price target of analysts on Wall Street is $7, which implies a decrease of -84.29% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $7 respectively. As a result, DNA is trading at a premium of 45.74% off the target high and 45.74% off the low.
Ginkgo Bioworks Holdings Inc (DNA) estimates and forecasts
Statistics show that Ginkgo Bioworks Holdings Inc has outperformed its competitors in share price, compared to the industry in which it operates. Ginkgo Bioworks Holdings Inc (DNA) shares have gone up 12.72% during the last six months, with a year-to-date growth rate more than the industry average at 35.77% against 16.50.
While earnings are projected to return 45.22% in 2025.
DNA Dividends
Ginkgo Bioworks Holdings Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s Major holders
Ginkgo Bioworks Holdings Inc insiders own 6.68% of total outstanding shares while institutional holders control 68.02%, with the float percentage being 72.89%. VIKING GLOBAL INVESTORS LP is the largest shareholder of the company, while 222.0 institutions own stock in it. As of 2024-06-30, the company held over 143.09 million shares (or 7.1383% of all shares), a total value of $47.83 million in shares.
The next largest institutional holding, with 138.96 million shares, is of VANGUARD GROUP INC’s that is approximately 6.9327% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $46.46 million.
